Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
Launched by BAYER · Sep 9, 2005
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic hypogonadism
- • Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study
- Exclusion Criteria:
- • Patients with any contraindication for testosterone use
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Innsbruck, , Austria
Napoli, , Italy
Dublin, , Ireland
Wien, , Austria
Leipzig, Sachsen, Germany
Madrid, , Spain
Tampere, , Finland
Barcelona, , Spain
Graz, , Austria
Bonn, Nordrhein Westfalen, Germany
Roma, , Italy
Salzburg, , Austria
Helsinki, , Finland
Oulu, , Finland
Halle, Sachsen Anhalt, Germany
Dresden, Sachsen, Germany
Magdeburg, , Germany
Milano, , Italy
Hospitalet De Llobregat, Barcelona, Spain
Goteborg, , Sweden
Malmo, , Sweden
Stockholm, , Sweden
Reading, Berkshire, United Kingdom
Wigan, Manchester, United Kingdom
Cardiff, , United Kingdom
London, , United Kingdom
Sheffield, , United Kingdom
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials